Triple angiokinase inhibitor (VEGFR/FGFR/PDGFR)

This mechanism describes small molecules designed to simultaneously block three related receptor tyrosine kinase families: vascular endothelial growth factor receptors (VEGFR), fibroblast growth factor receptors (FGFR), and platelet-derived growth factor receptors (PDGFR). Each family signals through its own ligand-receptor pair on the surface of endothelial cells, pericytes, and fibroblasts, driving new blood vessel formation (angiogenesis), vessel maturation, and tissue remodeling. By inhibiting all three pathways with one agent, rather than a single receptor family, the aim is to more completely interrupt the redundant and overlapping signals that tumors and fibrotic tissues use to recruit blood supply and supportive stroma; blocking VEGFR alone often allows tumors to compensate through FGFR- or PDGFR-driven vessel growth. This combined blockade is relevant in oncology, where starving a tumor of vascular support can slow growth, and in fibrotic lung disease, where aberrant fibroblast activity and vascular remodeling contribute to progressive scarring. The broader kinase coverage reflects a rationale of resistance mitigation and biological redundancy rather than simple potency, though it also broadens the range of tissues affected during treatment, since these same receptors have normal physiological roles in vessel maintenance and wound repair.